

CERTIFICATE

Survey of 25 October 2024

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Preeclampsia Marker (625):

Validity 12 months:

PLGF (placental growth factor)

sFLT-1 (soluble fms-like tyrosine kinase-1)

(R) analysis is subject to the RiliBÄK

Customer:

10071078

OKB MNUL, Ing. Adela Jizerova

Sociální péče 3316/12A

40113 Ústí nad Labem



Düsseldorf, 21 November 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Peter B. Luppa
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 25 October 2024

You have participated in the External Quality Assessment with the following analysis

Preeclampsia Marker (625):

PLGF (placental growth factor)

sFLT-1 (soluble fms-like tyrosine kinase-1)

(R) analysis is subject to the RiliBÄK

Customer:

10071078

OKB MNUL, Ing. Adela Jizerova

Sociální péče 3316/12A

40113 Ústí nad Labem



Düsseldorf, 21 November 2024



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Peter B. Lupp
(Adviser)

IN STAND

Gesellschaft zur Förderung der Qualitätssicherung
in medizinischen Laboratorien e.V.
Ublstr. 20 | 40223 Düsseldorf

Listing and evaluation of the results

10071078: OKB MNUL, Ing. Adela Jizerova

Survey of 25 October 2024

Adviser:

Prof. Dr. med. Peter B. Lupp





amedes MVZ für Laboratoriumsmedizin und
Mikrobiologie GmbH
Maximiliansstr. 38
80539 München

Tel.: +49 211 159213 0

Mail: p.luppa@tum.de

625

Preeclampsia Marker

Analyte	Sam- ple	Unit	Your value	Target value	TV- Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
PlGF (placental growth factor)	61	pg/ml	150	150	SV	128	173	0.0%	0	+	
	62		611	627	SV	533	721	-2.6%	-0,405	+	
sFLT-1 (soluble fms-like tyrosine kinase-1)	61	pg/ml	9823	8672	SV	5637	11707	13.3%	0,645	+	
	62		2795	2644	SV	1719	3569	5.7%	0,545	+	

Analyte	Sam- ple	Your unit	Stated value	Conversion factor	Method	Manu- facturer	Device
PlGF (placental growth factor)	61	ng/l	150	1.00		RO	RO88
	62		611	1.00			
sFLT-1 (soluble fms-like tyrosine kinase-1)	61	ng/l	9823	1.00		RO	RO88
	62		2795	1.00			

Additional information on the evaluation is available for download in the RV-Online system in the column "Report".

Individual summary of results

10071078: OKB MNUL, Ing. Adela Jizerova

Survey of 25 October 2024

625



Preeclampsia Marker

PLGF (placental growth factor) (pg/ml, N = 169)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
Roche	61	150	128 - 173	150	8.67	126	93.7	92.1	
	62	627	533 - 721	627	6.30	126	95.2		
Brahms Kryptor	61	153	130 - 176	153	4.54	36	97.2	97.2	
	62	575	489 - 661	575	3.11	36	97.2		
Siemens Atellica (1)	61	488	415 - 561	488	9.20	5			
	62	1555	1322 - 1788	1555	6.56	5			
other provider (1)	61	348	296 - 400	348	60.6	2			
	62	1211	1029 - 1393	1211	54.4	2			

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 92,3%



sFLT-1 (soluble fms-like tyrosine kinase-1) (pg/ml, N = 160)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
Roche	61	8672	5637 - 11707	8672	20.6	125	88.8	88.8	
	62	2644	1719 - 3569	2644	10.5	125	99.2		
Brahms Kryptor	61	3908	2540 - 5276	3908	22.5	28	92.9	92.9	
	62	1206	784 - 1628	1206	14.7	28	96.4		
Siemens Atellica (1)	61	41252	26814 - 55690	41252	30.3	5			
	62	9366	6088 - 12644	9366	17.3	5			
other provider (1)	61	22355	14531 - 30179	22355	109	2			
	62	5834	3792 - 7876	5834	82.0	2			

(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 88,8%

